Rafael Grochot
Overview
Explore the profile of Rafael Grochot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
4
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westaby D, Jimenez-Vacas J, Figueiredo I, Rekowski J, Pettinger C, Gurel B, et al.
J Clin Invest
. 2024 Sep;
134(18).
PMID: 39286979
The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage...
2.
Carmichael J, Figueiredo I, Gurel B, Beije N, Yuan W, Rekowski J, et al.
J Clin Invest
. 2024 Jun;
134(21).
PMID: 38833311
BACKGROUNDClinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports...
3.
Neeb A, Figueiredo I, Gurel B, Nava Rodrigues D, Rekowski J, Riisnaes R, et al.
Lab Invest
. 2023 Aug;
103(11):100245.
PMID: 37652207
BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of the androgen receptor, leading to prostate cancer development and progression. Studies investigating the clinical...
4.
Grochot R, Carreira S, Miranda S, Figueiredo I, Bertan C, Rekowski J, et al.
Eur Urol Open Sci
. 2023 Jun;
52:72-78.
PMID: 37284046
Background: Germline mutations in the ataxia telangiectasia mutated () gene occur in 0.5-1% of the overall population and are associated with tumour predisposition. The clinical and pathological features of -mutated...
5.
Chandran K, Grochot R, Fenor de La Maza M, Yuan W, Gurel B, Miranda S, et al.
Eur Urol
. 2023 Jan;
83(4):379-380.
PMID: 36609007
No abstract available.
6.
Pettinger C, Livings C, Grochot R, Furness A, Lopez J
J Immunother Cancer
. 2022 Dec;
10(12).
PMID: 36564127
Immune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets and...